
Glenmark signs deal with Novartis over distribution in Brazil
pharmafile | June 24, 2019 | News story | Sales and Marketing | Brazil, Glenmark, Latin America, Novartis, distribution, pharma
Indian firm Glenmark Pharmaceuticals has entered into an agreement with Novartis over the distribution of its respiratory products in Brazil.
Novartis will distribute three of Glenmark’s COPD drugs in Brazil from 1 July 2019.
The Swiss firm will be responsible for promoting, commercialising and distributing Glenmark’s Seebri (Glycopyrronium bromide), Onbrize (Indacaterol) and Ultibro (combination of Indacaterol and Glycopyrronium) – all of which treat the symptoms of COPD.
“This partnership is in line with our vision to expand our respiratory product offerings for patients and prescribers in Brazil and further consolidate our position in this segment,” said Glenn Saldanha, Chairman and Managing Director of Glenmark.
Glenmark receives around 5% of its revenue from Latin America. However Indian generic drugmakers – who are now facing pricing pressures in the US – are increasingly focused on increasing sales in big markets such as Brazil.
Louis Goss
Related Content

Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …

Scotland starts newborn screening for SMA
As part of a two-year evaluation funded by the Scottish government and Novartis, Scotland will …






